These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25929843)

  • 1. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
    J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T; Du J; Raynald ; Wang J; Li C
    World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
    Jóźwiak S; Nabbout R; Curatolo P;
    Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors.
    Danassegarane G; Tinois J; Sahler Y; Aouaissia S; Riffaud L
    Neurochirurgie; 2022 Dec; 68(6):627-636. PubMed ID: 35907444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
    Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
    Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
    Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
    Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
    Appalla D; Depalma A; Calderwood S
    Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
    Zipori AB; Tehrani NN; Ali A
    J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.
    Tsai JD; Wei CC; Tsao TF; Hsiao YP; Tsai HJ; Yang SH; Tsai ML; Sheu JN
    Childs Nerv Syst; 2016 Jan; 32(1):89-95. PubMed ID: 26552385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
    Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
    Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.